Ihre Suche nach:
10 Ergebnis(se) in 0.21 s
-
DUKAS_183263416_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS) wears a Medtronic device during treatment with neurologist Gaurav Chattree, Stanford University, not pictured, at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263412_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), walks in a hallway during his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), and other medical professionals at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263388_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Neurologist Gaurav Chattree, second from right, Stanford University, converses with Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), second from left, during treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263386_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Neurologist Gaurav Chattree, Stanford University, monitors treatment with Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), not pictured, at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263384_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Neurologist Gaurav Chattree, Stanford University, monitors treatment with Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), not pictured, at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263382_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), walks in a hallway during his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), and other medical professionals at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263378_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), left, displays his motor skills to neurologist Gaurav Chattree, Stanford University (center), and engineer Shrav Ravi, emerging technology field technical consultant with Medtronic, during treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263376_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), attends his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), (not pictured) at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263366_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), second from left, listens to neurologist Gaurav Chattree, not pictured, Stanford University, during treatment at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James -
DUKAS_183263364_POL
FDA approves deep-brain stimulation treatment for Parkinsons patients
3/21/2025 - Palo Alto, California, USA: Parkinson’s patient John L. Lipp, CEO, Friends of the Alameda Animal Shelter (FAAS), attends his treatment with neurologist Gaurav Chattree, Stanford University (not pictured), (not pictured) at the Stanford Neuroscience Health Center in Palo Alto, Calif. on Friday, March 21, 2025. The FDA has recently approved a personalized treatment for Parkinson's, adaptive deep-brain stimulation. For the first time in the U.S., Stanford experts are using it for patients. (Yalonda M. James / San Francisco Chronicle / Polaris) (FOTO:DUKAS/POLARIS)
©San Francisco Chronicle/Yalonda M. James